IP Library Granted Patent US 7,833,700
Granted Patent B2
US 7,833,700 · App. 10/239,172 · Granted Nov 16, 2010

Method of concentrating and recovering a viral enzyme activity from biological samples

Assignee: Cavidi AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,833,700
App. No.
10/239,172
Granted
Nov 16, 2010
Kind
B2
Abstract

A method of concentrating and recovering an enzyme activity from enveloped viruses present in a biological sample, is described. The method comprises contacting the biological sample in a first buffer solution with a virus-binding matrix, such as an anion exchanger matrix, to attach virus particles present in the sample to the matrix, washing the matrix carrying the virus particles with a second buffer solution to remove components interfering with viral enzyme activity, lysing the immobilized virus particles in a third buffer solution and recovering the concentrated viral enzyme activity from the third buffer solution. Additionally, a commercial package containing written and/or data carrier instructions for performing laboratory steps for concentration and recovery of an enzyme activity from enveloped viruses present in a biological sample and at least one component necessary for the assay, is disclosed.

Claims (30)

1. Method of concentrating and recovering a reverse transcriptase (RT) enzyme activity from enveloped retroviruses present in a biological sample

comprising the steps of

contacting the biological sample in a first buffer solution at a concentration in range of 100-500 mM of buffering substance and having a pH of 4.0-8.5 and optionally containing chaothropic ions at an ionic strength of up to 2 M with a virus-binding matrix, to attach virus particles present in the sample to the matrix,

washing the matrix carrying the virus particles with a second buffer solution at a concentration of 1-100 mM of buffering substance and containing cations at a concentration of 0.1-1 M and having a pH of 4-9, to remove components interfering with viral enzyme activity,

lysing the immobilized virus particles in a third buffer solution at a concentration of 10-500 mM of buffering substance and containing a non denaturing detergent and having a pH of 4-9 which prevents the enzyme from binding to the virus-binding matrix, and

recovering the concentrated viral enzyme activity from the third buffer solution.

2. Method according to claim 1 , wherein the virus-binding matrix is an anion exchanger matrix.

3. Method according to claim 2 , wherein the anion exchanger matrix contains tertiary and/or quaternary amine groups.

4. Method according to claim 1 , wherein the first buffer is selected from the group consisting of 150 mM MES pH 6.0, 200 mM Potassium iodide (KI).

5. Method according to claim 1 , wherein the second buffer is selected from the group consisting of 10 mM MES pH 6.0, 500 mM Potassium acetate (KAc).

6. Method according to claim 1 , wherein the third buffer is selected from the group consisting of enzyme assay compatible buffers including a detergent and a buffering substance.

7. Method according to claim 1 , wherein the biological sample is selected from the group consisting of serum and plasma samples.

8. Commercial package containing written and/or data carrier instructions for performing laboratory steps for concentration and recovery of a reverse transcriptase enzyme activity from enveloped retroviruses present in a biological sample, and

the components

a virus-binding matrix,

a first buffer solution at a concentration in range of 100-500 mM of buffering substance and having a pH of 4.0-8.5 and containing chaothropic ions at an ionic strength of up to 2 M,

a second buffer solution at a concentration of 1-100 mM of buffering substance and containing cations at a concentration of 0.1-1 M and having a pH of 4-9,

a third buffer solution at a concentration of 10-500 mM of buffering substance and containing a non denaturing detergent and having a pH of 4-9, and optionally

Mini columns, and

Plastic tubes.

9. Commercial package according to claim 8 , wherein the virus-binding matrix is an anion exchanger matrix,

the first buffer is selected from the group consisting of 150 mM MES pH 6.0, 200 mM

Potassium iodide (KI),

the second buffer is selected from the group consisting of 10 mM MES pH 6.0, 500 mM

Potassium acetate (KAc),

the third buffer is selected from the group consisting of enzyme assay compatible buffers including a detergent and a buffering substance.

10. Commercial package according to claim 9 , wherein the anion exchanger matrix contains tertiary and/or quaternary amine groups.

11. Method according to claim 2 , wherein the first buffer is selected therefor the group consisting of 150 mM MES pH 6.0, 200 mM Potassium iodide (KI); the second buffer is selected from the group consisting of 10 mM MES pH 6.0, 500 mM Potassium acetate (KAc); and wherein the third buffer is selected from the group consisting of enzyme assay compatible buffers including a detergent and a buffering substance.

12. Method according to claim 11 , wherein the biological sample is selected from the group consisting of serum and plasma samples.

13. Method according to claim 12 wherein the RT activity is quantitated with a sensitive assay.

Assignments (3)
SECURITY INTEREST Recorded Aug 7, 2015
From: CAVIDI AB
To: EUROPEAN INVESTMENT BANK
Reel/Frame 036280/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2010
From: CAVIDI TECH AB
To: CAVIDI AB
Reel/Frame 024974/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2002
From: MALMSTEN, ANDERS; PETTERSSON, INGVAR; GATU, TOMMY; KALLANDER, CLAS; GRONOWITZ, SIMON
To: CAVIDI TECH AB
Reel/Frame 013469/0384 →
Priority Claims (1)
SE 0001132 · Mar 29, 2000 · national
Continuity (1)
Related Publication 20030104441A1 · Jun 5, 2003